Patents by Inventor Hanna LESCH

Hanna LESCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230374540
    Abstract: “MAAP” is a naturally-occurring, newly-discovered about 13 KDa adeno-associated vims protein. It is not homologous to known proteins. When AAV producer cells are cultured for more than 24 hours, we found that inactivating translation of the full-length MAAP improves the productivity of the transfected producer cells. The resulting AAV viruses are also of better quality and more stable. Our findings thus provide a way to improve the industrial manufacture of recombinant adeno-associated virus gene therapy vectors.
    Type: Application
    Filed: June 25, 2021
    Publication date: November 23, 2023
    Inventors: Lionel GALIBERT, Kari AIRENNE, Amira HYVÖNEN, Reetta ERIKSSON, Hanna Lesch, Justin Darius ALBERS
  • Publication number: 20200354409
    Abstract: Producing adenovirus gene therapy vector in producer cells that express or over-express adenoviral polypeptide IX enables one to produce pIX-deleted adenovirus in suspension cell culture. Using producer cells that express or over-express adenoviral polypeptide IX also increases the yield of adenovirus vector, regardless of whether that adenovirus is pIX-deleted. Using producer cells that express or over-express adenoviral polypeptide IX also improves the resulting vector's transduction kinetics, reducing the number of pfu/target cell required to achieve a given level of transduction/infection, shortening the time the vector requires to transduce or infect a target cell, and shortening the time an infected target cell produces progeny virus.
    Type: Application
    Filed: September 13, 2019
    Publication date: November 12, 2020
    Applicant: Kuopio Center for Gene and Cell Therapy Oy
    Inventors: Vesa TURKKI, Saana LEPOLA, Hanna LESCH, Seppo YLA-HERTTUALA
  • Publication number: 20190315808
    Abstract: Producing adenovirus gene therapy vector in producer cells that express or over-express adenoviral polypeptide IX enables one to produce pIX-deleted adenovirus in suspension cell culture. Using producer cells that express or over-express adenoviral polypeptide IX also increases the yield of adenovirus vector, regardless of whether that adenovirus is pIX-deleted. Using producer cells that express or over-express adenoviral polypeptide IX also improves the resulting vector's transduction kinetics, reducing the number of pfu/target cell required to achieve a given level of transduction/infection, shortening the time the vector requires to transduce or infect a target cell, and shortening the time an infected target cell produces progeny virus.
    Type: Application
    Filed: May 28, 2019
    Publication date: October 17, 2019
    Applicant: Kuopio Center for Gene and Cell Therapy Oy
    Inventors: Vesa TURKKI, Saana LEPOLA, Hanna LESCH